1. Home
  2. IMSR vs CRBU Comparison

IMSR vs CRBU Comparison

Compare IMSR & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IMSR

Terrestrial Energy Inc.

N/A

Current Price

$6.42

Market Cap

233.8M

Sector

N/A

ML Signal

N/A

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.87

Market Cap

203.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMSR
CRBU
Founded
2013
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.8M
203.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
IMSR
CRBU
Price
$6.42
$1.87
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
1.2M
1.2M
Earning Date
01-01-0001
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.64
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.95
$0.66
52 Week High
$16.38
$3.53

Technical Indicators

Market Signals
Indicator
IMSR
CRBU
Relative Strength Index (RSI) 40.99 53.25
Support Level $5.98 $1.70
Resistance Level $7.59 $2.11
Average True Range (ATR) 0.57 0.14
MACD 0.07 -0.00
Stochastic Oscillator 26.11 37.72

Price Performance

Historical Comparison
IMSR
CRBU

About IMSR Terrestrial Energy Inc.

Terrestrial Energy Inc is an industry-leading technology company committed to delivering reliable, emission-free, and cost-competitive nuclear energy with a transformative advanced reactor, the Integral Molten Salt Reactor (IMSR). Its mission is to transform global energy markets by commercializing its IMSR Plant, which will deliver low-carbon electricity and industrial heat with superior economics, speed to deployment, and siting flexibility.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Share on Social Networks: